ID23921A - Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi - Google Patents

Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi

Info

Publication number
ID23921A
ID23921A IDW20000819A ID20000819A ID23921A ID 23921 A ID23921 A ID 23921A ID W20000819 A IDW20000819 A ID W20000819A ID 20000819 A ID20000819 A ID 20000819A ID 23921 A ID23921 A ID 23921A
Authority
ID
Indonesia
Prior art keywords
categol
indazola
bioisostere
therapy
replacement
Prior art date
Application number
IDW20000819A
Other languages
English (en)
Indonesian (id)
Inventor
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID23921A publication Critical patent/ID23921A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20000819A 1997-11-04 1998-10-26 Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi ID23921A (id)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6422897P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6419897P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
ID23921A true ID23921A (id) 2000-05-25

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000819A ID23921A (id) 1997-11-04 1998-10-26 Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi

Country Status (29)

Country Link
US (1) US6391872B1 (fr)
EP (1) EP1028946A1 (fr)
JP (1) JP2001521926A (fr)
CN (1) CN1284948A (fr)
AP (1) AP910A (fr)
AR (1) AR013746A1 (fr)
AU (1) AU754734B2 (fr)
BG (1) BG104450A (fr)
BR (1) BR9813926A (fr)
CA (1) CA2309150A1 (fr)
CZ (1) CZ20001621A3 (fr)
DZ (1) DZ2640A1 (fr)
EA (1) EA200000488A1 (fr)
HR (1) HRP20000253A2 (fr)
HU (1) HUP0004150A3 (fr)
ID (1) ID23921A (fr)
IL (1) IL135900A0 (fr)
IS (1) IS5465A (fr)
MA (1) MA26563A1 (fr)
NO (1) NO20002129L (fr)
NZ (1) NZ503918A (fr)
OA (1) OA11354A (fr)
PE (1) PE129199A1 (fr)
PL (1) PL340753A1 (fr)
SK (1) SK6252000A3 (fr)
TN (1) TNSN98200A1 (fr)
TR (1) TR200001234T2 (fr)
WO (1) WO1999023077A1 (fr)
YU (1) YU25000A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
JP2003507342A (ja) * 1999-08-12 2003-02-25 アメリカン・サイアナミド・カンパニー 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
NZ532278A (en) 2001-09-19 2006-02-24 Altana Pharma Ag Combination of a PDE inhibitor and an NSAID
WO2003024456A1 (fr) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement et de prevention des migraines
AU2003201149A1 (en) * 2002-02-13 2003-09-04 Koninklijke Philips Electronics N.V. Integrated semiconductor optical device, method and apparatus for manufacturing such a device
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
EP2108370A1 (fr) * 2002-04-30 2009-10-14 Unigen Pharmaceuticals, Inc. Formulation d'un mélange de flavonoïdes et de flavanes à cycle B libre et de flavanes en tant qu'agent thérapeutique
BR0316950A (pt) 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf
BRPI0407253A (pt) * 2003-02-14 2006-01-31 Wyeth Corp Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040220119A1 (en) * 2003-04-04 2004-11-04 Unigen Pharmaceuticals, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
CA2557575A1 (fr) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Derives fusionnes de pyrazole
CA2558109A1 (fr) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Derives pyrazolo heteroaryl-condenses
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
CN101111494A (zh) * 2004-11-29 2008-01-23 沃纳-兰伯特有限公司 具有治疗作用的吡唑并[3,4-b]吡啶和吲唑
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007032833A1 (fr) * 2005-08-15 2007-03-22 Wyeth Dérivés d’azinyl-3-sulfonylindazole en tant que ligands de 5-hydroxytryptamine-6
WO2007023111A2 (fr) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Inhibiteurs de la map-kinase p38 et leurs methodes d'utilisation
EP1928866A1 (fr) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP2628725A1 (fr) * 2005-11-03 2013-08-21 Allergan, Inc. Prostaglandines et analogues en tant qu'agents pour abaisser la pression intraoculaire
CN101370775A (zh) 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
SI1981851T1 (sl) 2006-01-31 2012-05-31 Array Biopharma Inc Kinazni inhibitorji in postopki za njihovo uporabo
US7829713B2 (en) 2006-02-28 2010-11-09 Helicon Therapeutics, Inc. Therapeutic piperazines
US8084485B2 (en) 2006-03-31 2011-12-27 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
EP2001865A1 (fr) * 2006-04-05 2008-12-17 Wyeth a Corporation of the State of Delaware Dérivés de sulfonyl-3-hétérocyclylindazole utilisés en tant que ligands de la 5-hydroxytryptamine-6
WO2007120596A1 (fr) * 2006-04-12 2007-10-25 Wyeth DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
EP2569301A1 (fr) 2010-05-12 2013-03-20 Abbvie Inc. Inhibiteurs indazoliques des kinases
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
WO1989003385A1 (fr) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
EP0912558B1 (fr) * 1996-06-25 2003-07-09 Pfizer Inc. Derives d'indazole substitues et leur utilisation en tant qu'inhibiteurs de phosphodiesterase (pde) type iv et du facteur de necrose tumorale (tnf)
DE69709493T2 (de) * 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
CA2264798A1 (fr) * 1996-09-04 1998-03-12 Pfizer Inc. Derives d'indazole et leur utilisation en tant qu'inhibiteurs de phosphodiesterase (pde) de type iv et de la production du facteur de necrose des tumeurs (tnf)
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors

Also Published As

Publication number Publication date
PL340753A1 (en) 2001-02-26
IS5465A (is) 2000-04-19
TNSN98200A1 (fr) 2005-03-15
TR200001234T2 (tr) 2000-08-21
DZ2640A1 (fr) 2003-03-08
WO1999023077A1 (fr) 1999-05-14
EA200000488A1 (ru) 2000-10-30
NO20002129L (no) 2000-07-03
AU9455298A (en) 1999-05-24
OA11354A (en) 2003-12-23
HUP0004150A2 (hu) 2001-05-28
NO20002129D0 (no) 2000-04-26
JP2001521926A (ja) 2001-11-13
IL135900A0 (en) 2001-05-20
HUP0004150A3 (en) 2001-08-28
YU25000A (sh) 2003-12-31
BR9813926A (pt) 2000-09-19
CA2309150A1 (fr) 1999-05-14
EP1028946A1 (fr) 2000-08-23
CZ20001621A3 (cs) 2001-08-15
AP910A (en) 2000-12-05
NZ503918A (en) 2002-03-28
US6391872B1 (en) 2002-05-21
BG104450A (en) 2000-12-29
MA26563A1 (fr) 2004-12-20
SK6252000A3 (en) 2001-11-06
AP9801375A0 (en) 1998-12-31
CN1284948A (zh) 2001-02-21
HRP20000253A2 (en) 2001-06-30
PE129199A1 (es) 1999-12-16
AU754734B2 (en) 2002-11-21
AR013746A1 (es) 2001-01-10

Similar Documents

Publication Publication Date Title
ID23921A (id) Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi
ID22878A (id) Komposisi aktif secara terapi
NO20002127D0 (no) Terapeutiske aktive forbindelser basert pÕ indazol-bioster erstatning av catechol i PDE4 inhibitorer
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
IS5760A (is) Meðferðarlegar bíarýl afleiður
FI952033L (fi) Farmakologisesti aktiiviset pyrrolopyrimidiinijohdannaiset
EE04190B1 (et) Asendatud bensopüraani derivaatide kasutamine põletiku raviks
NO992806L (no) Terapeutiske midler
FI971412L (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
DK1020462T3 (da) Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
DE69823360D1 (de) Feste arzneizubereitung enthaltend benzofuranderivate
ID18679A (id) Penggunaan terapi lanjutan
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
ID24677A (id) Kombinasi senyawa aktif fungisidal
SI0922703T1 (en) Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
ID24922A (id) Terapi kombinasi untuk pengobatan aids
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
GB9822950D0 (en) Therapeutic use of matrix metalloproteinase inhibitors
GB9713240D0 (en) Heterocyclic compounds and their therapeutic use
HU9700442D0 (en) Compounds of pharmaceutical activity
SE9702595D0 (sv) new therapeutic use
ID19095A (id) Senyawa terapeutik fenetanolamina
GB9820768D0 (en) Heterocyclic compounds and their therapeutic use